Surgical Science has today published its Annual Report for 2025. The document is attached to this press release and is also available at www.surgicalscience.com. Printed copies are sent to shareholders who so request and state their postal address.


Gothenburg, Sweden, April 15, 2026
Surgical Science Sweden AB (publ)


The Annual Report is available in the attachment or via
https://surgicalscience.com/investor-relations/#press-releases
https://surgicalscience.com/aktien/financial-report

For further information, please contact:

Tom Englund, CEO
Telephone: +46-70-916 16 81
E-mail: tom.englund@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

Surgical Science is a global leader in evidence-based medical simulation. The company’s virtual reality simulators and customized training solutions enable surgeons and healthcare professionals to practice and improve their skills outside the operating room - enhancing patient safety and clinical outcomes. Also, Surgical Science partners with medical technology and robotics companies to integrate tailor-made simulation technology into their devices, helping them accelerate innovation and gain a competitive edge. 

Surgical Science has approximately 310 employees. The company is headquartered in Gothenburg, Sweden, and has operations in Tel Aviv, Israel; Stockholm, Sweden; Cleveland, US; and Cardiff, UK. Through sales offices in these markets and in China, as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market, Stockholm, Sweden. Certified Adviser is DNB Carnegie Investment Bank AB. 

Attachments

SuS AR25 EN

Läs mer på MFN